中国药房2024，Vol.35Issue(17)：2165-2170,6.DOI:10.6039/j.issn.1001-0408.2024.17.19
以凝血因子Ⅺ作为靶点的抗凝血药研究进展
Research progress of anticoagulant drugs targeting coagulation factor Ⅺ
摘要
Abstract
Anticoagulants are the cornerstone of the prevention and treatment of thromboembolic diseases.Existing parenteral and oral anticoagulants achieve effective control of thrombosis by interfering with key aspects of the coagulation cascade reaction,but this is accompanied by an increased risk of bleeding.FⅪ inhibitors,anticoagulants targeting coagulation factor Ⅺ(FⅪ),can block the amplification phase of the thrombin generation process by inhibiting FⅪ,reducing thrombogenesis with less impact on normal hemostatic effects,and have become one of the most promising new anticoagulants.There are currently no marketed FⅪinhibitor drugs,while FⅪ inhibitors in phase Ⅱ or phase Ⅲ clinical trials include 3 classes:antisense oligonucleotide,monoclonal antibody and small molecule inhibitors.In addition,most of the natural inhibitors and nucleic acid aptamers targeting FⅪ are under preclinical development.As new target drugs for anticoagulation therapy,FⅪ inhibitors are expected to become a safer and more effective therapeutic option,compensating for the limitations of current anticoagulants and providing patients with more effective thromboprophylaxis and therapeutic options while reducing the risk of bleeding.关键词
抗凝血药/凝血因子Ⅺ/血栓形成/FⅪ抑制剂/血栓栓塞性疾病Key words
anticoagulants/coagulation factor Ⅺ/thrombosis/FⅪ inhibitors/thromboembolic disease分类
医药卫生引用本文复制引用
苑新文,赵振宇..以凝血因子Ⅺ作为靶点的抗凝血药研究进展[J].中国药房,2024,35(17):2165-2170,6.基金项目
天津市医学重点学科建设项目(No.TJYXZDXK-032A) （No.TJYXZDXK-032A）
